There are 3161 resources available
1317P - Real-world immunotherapy (IO) rechallenge outcomes with nivolumab (NIV) in advanced non-small cell lung cancer (aNSCLC) in France: LIST study interim results
Presenter: Benoit Godbert
Session: Poster session 05
1318P - Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)
Presenter: Caicun Zhou
Session: Poster session 05
1319P - Impact of concomitant co-medications on survival with first-line pembrolizumab in 43,000 French patients with advanced NSCLC
Presenter: Adrien Rousseau
Session: Poster session 05
1320P - Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy
Presenter: Arsela Prelaj
Session: Poster session 05
1322P - A phase II trial of autologous cytokine-induced killer (CIK) therapy plus toripalimab with or without chemotherapy as first-line treatment in advance NSCLC
Presenter: Baohui Han
Session: Poster session 05
Resources:
Abstract
1323P - RATIONALE-307 long-term outcomes: First-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone for advanced squamous (sq) NSCLC
Presenter: Zhijie Wang
Session: Poster session 05
1324P - Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Presenter: Valerie Gounant
Session: Poster session 05
1325P - TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Presenter: Ferdinandos Skoulidis
Session: Poster session 05
1326P - Clinical and genomic characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) with long-term response to first-line (1L) immunotherapy: A real-world study
Presenter: Sameh Daher
Session: Poster session 05
1327P - Lung immune prognostic index (LIPI) as a guide for addition of chemotherapy in immunotherapy in elderly patients (Pts) with non-small cell lung cancer (NSCLC): NEJ057
Presenter: OSAMU HONJO
Session: Poster session 05